Tocagen has formed strategic alliances with MRI Interventions and Brainlab to visualise local drug delivery in patients suffering from recurrent glioblastoma multiforme brain cancer.

Under the alliance, Tocagen will utilise MRI Interventions’ ClearPoint neuro intervention system at selected sites in its ongoing investigational clinical trial for the delivery of Toca 511 into brain tumours, under magnetic resonance imaging (MRI) guidance.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

As a retroviral replicating vector (RRV), Toca 511 is designed to deliver a cytosine deaminase gene selectively to cancer cells, which then converts the flucytosine (FC) prodrug into the anti-cancer drug 5-fluorouracil.

“Tocagen is currently enrolling patients in its investigational, open-label, multicentre trial to assess the safety and efficacy of Toca 511.”

Tocagen is currently enrolling patients in its investigational, open-label, multicentre trial to assess the safety and efficacy of Toca 511 when injected into the brain tumour and followed by oral administration of Toca FC in patients with recurrent glioma.

Neurosurgeons participating in the Tocagen clinical trial plan to use the ClearPoint system to place the catheter into the brain tumour and then deliver Toca 511 directly into the tumour, while observing the delivery in real time via MRI.

Patient enrolment is currently underway at one of the several trial centres for the multicentre Phase 1/2 study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MRI Interventions CEO, Kimble Jenkins, said: “Excitement among researchers and drug companies to explore use of the ClearPoint system for direct drug delivery began to build last year, on the heels of two research publications from UCSF.”

Joseph Doyle, Brainlab CFO, said: “By offering a platform for delivering therapeutic agents direct to the central nervous system, we hope to make promising therapies more accessible to patients.”